Last updated: 2026-10-15 22:35:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
BillionToOne, Inc. (BLLN) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $102.77, with a market capitalisation of $4.46B and a P/E ratio of 153.64. Over the past 52 weeks, its price has ranged from $61.96 to $150.44. This page covers its latest market performance, valuation, price trends and company information.
$4.46B | |
$101.64 | |
$150.44 | |
$61.96 | |
$97.88 | |
123.86K | |
678.26K | |
153.64 | |
$150.44 | |
$61.96 | |
-- | |
-- |
BillionToOne, Inc. (BLLN) is trading at $102.77 in after-hours trading as of 2026-10-15 22:13:00, up 4.99% ($4.89) from the regular-session close of $97.88.
After-hours trading shows how investors are pricing BLLN after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, BillionToOne, Inc. (BLLN) moved from $99.94 to $102.77, representing a gain of 2.83% ($2.83).
The stock traded between $90.48 and $112.87 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 584.25 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 46.1%
BLLN is currently trading at $102.77, placing it 46.1% of the way from its 52-week low of $61.96 to its 52-week high of $150.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 713 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BillionToOne, Inc. (BLLN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.